Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
These sold at local BMW Ducati dealership lots of locations across US and....
I guess i am missing the point what $Alyi brings to the table and time to market issues. Seems like these guys could do the same? Don’t know. Anyway just sold 200k of Alyi as news today fell flat. Seems as though they use a lot of name dropping without any direct relationship with $ALYI. That worries me. It was a fin tide more than doubling $$ just be careful with this one,
Did a search for electric motorcycles and found this competitor. Just some food for thought? https://www.zeromotorcycles.com/
$ALYI NEWS RELEASE NOW ACCEPTING ORDERS.... https://www.newsfilecorp.com/release/71938/
Do you have a link to this data?
Yesterday the filed for “Termination of Registration of a Class of Security Under Section 12(g) (15-12g)”. I got the impression they are being delisted on the OTC. Anyone have a good read on this?
I Concur. I have been here for a long time and these things take strength In patience, especially in pharmaceuticals and approvals, add to that disruptive technology acceptances as well. I am purely deliverable based, they have a product time line let’s see how they execute, these are measurable.
Got mine this morning also from Fidelity I voted Against reverse split 700-1 and Against them trying again if they don’t get enough votes during the meeting. I have seen this go badly for investors before. Been burnt once, an thew away $11k here already not intentionally but due to OWCP poor management. Very disappointed in the company.
Voted NO here as well also no on bringing this up again later!! Actions just Do not make any sense!! I am hold $xx,xxx.00 investment oops $xxx.00 stock now OMG 99% depreciation!! Yes I am ticked off as well. Just execute product plans and get to market don’t play with investor just to look good and get toxic funding.
Received mine a couple weeks ago via Fidelity investments notification was able to vote online no problems.
Outstanding summary post recommend posting this to the sticky page on top for others to read. Good stuff nice work!
Great summary Boo Dog! I think when the trials get rolling the PPS momentum will be incredible! Thanks
Boo yah! UT confirmation, news, direction and timeline all comes down to execution now. Still picking up shares while they are cheap!
Great news article from seeking Alpha just release minutes ago. InMed Pharmaceuticals Closer To One-Year Commercialization And Revenues $IMLFF https://seekingalpha.com/article/4211976
OncBioMune Advancing ProscaVax Towards Second Phase 2 Clinical Trial for Prostate Cancer with Protocol Submission to FDA
BY GLOBENEWSWIRE — 8 MINUTES AGO
BATON ROUGE, La., Oct. 11, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to announce that the protocol for the planned Phase 2 clinical trial of ProscaVax for advanced prostate cancer to be hosted at Urology Clinics of North Texas (UCNT) has been submitted to the U.S. Food and Drug Administration for approval to initiate the study. We expect the FDA and IRB process to move quickly and have the first patient injected before the first of December.
The trial is designed to build upon a successfully completed Phase 1a trial of ProscaVax in patients with advanced prostate cancer that have failed previous therapy with documented rising prostate specific antigen (PSA). In the Phase 1a trial, ProscaVax, the Company’s lead immunotherapy platform candidate consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), was shown to be safe and well tolerated.
At 19 weeks post-therapy, 80 percent of patients (n=20) in the Phase 1a trial demonstrated stable disease/no prostate cancer progression. Of those 16 patients, 12 completed additional follow-up examinations at 43 weeks post-therapy. Overall survival was 100% for all 20 patients and 12 of the 17 evaluable patients (70.6%) continued to live with stable/progression-free disease.
The latest study is structured to expeditiously add to the body of clinical evidence supporting the safety and efficacy of ProscaVax by using an independent Institutional Review Board and accessing for enrollment the large population of prostate cancer patients being treated at UCNT. UCNT is a premier urology group with ten centers in North Texas and a team that includes 12 physicians honored with inclusion in the peer-selected “The Best Doctors in America” list.
“We are thrilled to be working with the esteemed prostate cancer experts at UCNT and to have completed all necessary negotiations and protocol finalizations to move towards a second clinical trial of ProscaVax in late-stage patients. We believe that ProscaVax will again be able to deliver a meaningful therapeutic benefit to these patients with advanced disease that currently are presented with almost no safe and effective options,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Combined with the initiation of the world’s first ever study of a vaccine in early-stage prostate cancer patients in ‘active surveillance’ at a teaching hospital of Harvard University, we are steadily building our position as a leader in immunotherapy with a novel approach to prostate cancer. As we grow this footprint, we believe that there will be an increase in our market valuation followed by potential partnering opportunities.”
About Prostate Cancer
According to the American Cancer Society (ACS), prostate cancer is the most common type of cancer in men other than skin cancer, with about 1 in 9 men diagnosed during their lifetime. ACS estimates that about 164,690 new cases of prostate cancer will be diagnosed during 2018 and approximately 29,430 men will die from the disease this year. Prostate cancer is the second leading cause of cancer death in men, trailing only lung cancer. Approximately 2.9 million men are living with prostate cancer today. The average age of diagnosis is 66, with the disease considered rare in men under the age of 40.
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About OncBioMune Pharmaceuticals, Inc. (OBMP)
OncBioMune Pharmaceuticals (OBMP) is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, based on their proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. Our lead pipeline product, ProscaVax™, has successfully completed enrollment and vaccination of 20 prostate cancer patients and is collecting long-term follow-up results for the 1a portion of their Phase 1a/1b clinical trial. Due to the impressive results and proven safety profile of ProscaVax™, OncBioMune is forgoing the 1b portion of the trial to advance ProscaVax™ into Phase 2 studies. A Phase 2 trial is scheduled to commence at Beth Israel Deaconess Medical Center a Harvard University teaching hospital evaluating ProscaVax as a front-line therapy in prostate cancer patients in the “active surveillance” category, representing the first mid-stage trial of an immunotherapeutic vaccine in this patient population. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
Speculation of possibilities. I was on a Veterans Administration web cast yesterday where the directors spoke about exploration of non-opioid treatment exploration for chronic pain treatment. The director discussed VA investigating the non addictive benefits of non THC Cannabinoids.
Wow makes you think how InMed could play a leading role if they were to get engaged. Sound like something perfect. I think this is one of the many many future opportunities for tremendous $$$ upsides when they are in production.
Very cool, what was the date on the article. I noticed very low volume today, tight holding pattern no one was willing to move or sell meaningful volume or $$. I also believe this is getting ready to explode in steps. No doubt it will, just when? I have maxed out on shares just waiting and holding. Have a great trading day.
As long as we’re Blue Skying it think bigger. Past successful phase 2 & 3.
What if you used the same number of outstanding shares and it was bought out by big Pharma. For instance...
Onyx Pharmaceuticals, acquired by Amgen amgn in 2013 for $9.7 billion. Former Amgen executive Terry Rosen started Flexus Biosciences and sold it 17 months later for $1.3 billion.
So here’s a what if happy dreams for all us longs. Say they knocked it out the park in trials and FDA approvals. What if we used $9.7B from the above example, that is in the neighborhood of $39.63 per share. Of course there would be a lot more they would need to do make that happen in the next few years to work. But sweet dreams... what would your holding be worth? Makes you think twice about selling in the pennies versus holding strong. I think the total investors in this company is only about ~178 now before the crowd rushes in.
Anyway just a Sunday afternoon dream. Happy trading on Monday.
As long as we’re Blue Skying it think bigger. Past successful phase 2 & 3.
What if you used the same number of outstanding shares and it was bought out by big Pharma. For instance...
Onyx Pharmaceuticals, acquired by Amgen amgn in 2013 for $9.7 billion. Former Amgen executive Terry Rosen started Flexus Biosciences and sold it 17 months later for $1.3 billion.
So here’s a what if happy dreams for all us longs. Say they knocked it out the part in trails and FDA approvals. What if we used $9.7B from the above example, that is in the neighborhood of $39.63 per share. Of course there would be a lot more that would need to happen in the next few years to make that work. But sweet dreams... what would your holding be worth? Makes you think twice about selling in the pennies versus holding strong. I think the total investors in this company is only about ~178 now before the crowd rushes in.
Any just a Sunday afternoon dream happy trading on Monday.
Big spread between ask and bid today. Looks like this may be headed up if ask holds strong. Zero volume so far so ask is holding so far but the day is young.
8-k just posted OBMP received $150k in financing with private investor @8% due in one year and option could be converted into shares st a 25% discount to closing average over 5 days. I think this is a good thing keeping things rolling. I’d say that is a vote of confidence from a private investor, looks like in the same page as the “holding longs”. My sense is more good news is on the way. Awaiting trail patient selection closure by Aug 15.
I am sitting on a maxed out number shares even moved monies over from another investment, wish I could buy more, but in a great position, just sitting waiting..... Holding Long on $OBMP. I agree great things coming! Trial study due to begin Aug 14. Waiting info on TX and 10K next. Looks like buying pressure on the rise, I expect this will pull PPS to new higher plateaus next couple weeks. Any guesses?
Great reply awesome conclusions I am on the same page,
Thanks for the complement! I think it is important we all do our best on this board to crowd research actionable valid data. I am with you, I don’t know when it’ll hit but I am confident at this point it will happen big time! The market size is $13-15 Bullion for prostate and certainly large for the breast cancer follow-on as well. With solid patients and great trial results they’ll be golden for growth, of course lots of lean times for small start ups great risk and great rewards. I am fully loaded up and holding strong. I have narrowed my investments primarily to this one and a biosynthesized Cannabinoid Pharmaceutical company, similar technology as insulation production both huge potential in the medical arena.
Thanks, I appreciate the compliments. I don’t have the ability to make it a sticky perhaps someone else can do it?
Here is some DD research on patients all active. 15 patents and patents pending covering approximately 50 countries worldwide.
“Our patent portfolio is now very robust, including covering ProscaVax in key markets, including the U.S., Mexico and now Europe,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Protection of intellectual property is integral to our strategy to become a global pharmaceutical brand.”
1. Mexican Institute of Industrial Property has issued patent No. 343266, titled “Composition and Method for Treating Cancer,” protecting the intellectual rights of OncBioMune’s ProscaVax throughout Mexico until January 8, 2032.
2. patent No. 6118730 has been granted by the Japan Patent Office. The patent, titled, “Composition and Method for Treating Cancer,” protects the intellectual rights of OncBioMune’s ProscaVax in Japan until January 8, 2032.
3. European Patent Office has approved the Company’s patent application number 12701292.0 protecting ProscaVax as a PSA (prostate specific
4. Granted US Patent # 9,333,189 B2 on May 10, 2016 from the U.S. Patent and Trademark Office (USPTO), titled “Taxane-and taxoid-protein compositions.
5. A continuance of the original US patent application #13/017,173 is being pursued to also patent a paclitaxel-albumin drug which is similar to Celegene’s Abraxane.
6. Grant of Patent Right for Invention No. 201080005114.4 from China’s State Intellectual Property Office. The patent covers ProscaVax.
7. Patients, from Hong Kong’s patent office. The patent, titled “Composition and Method for Treating Cancer,” application number 14101607.7, protects ProscaVax in Hong Kong through January 8, 2032. Expands the scope of protection of OncBioMune’s intellectual property, which now includes 15 patents and patents pending covering approximately 50 countries worldwide for the Company’s vaccine and paclitaxel gallium transferrin (PGT) technologies.
8. Patients, from the European Patent Office. The patent, titled “Composition and Method for Treating Cancer,” application number 12701292.0, expands the scope of protection of OncBioMune’s intellectual property
9. Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application #13/017,173 that covers the Company’s transferrin transport technology for developing new, targeted cancer treatments. The patent to be issued from this allowed application, titled “Taxane-and taxoid-protein compositions,” carries a patent term to at least 2031.
10. Ukraine & China: from the State Intellectual Property Office (SIPO) of the People’s Republic of China (PRC) and the State Enterprise “Ukrainian Institute of Industrial Property” (Ukrainian Patent Office). The patents, titled “Composition and Method for Treating Cancer” — Appln, No. 201080005114.4 (PRC) and Appln. No. A 2013 09855 (Ukraine) – add to the intellectual property of ProscaVax™ and protect the vaccine through 2031. A previous patent for ProscaVax™ has been granted in the United States (U.S. Patent 8,647,627), and another related U.S. Patent application has recently received a Notice of Allowance (U.S. application 14/137,060)
————————————————————
1. Here is a link to their US patient. You can use the search to find more.....
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9333189.PN.&OS=PN/9333189&RS=PN/9333189
Found it! This is the video that first turned me onto OBMP$ and subsequent investments,
https://vimeo.com/183563997
Enjoy
With a $16-18B market and 6% CAGR it’s not hard to see what success in the market place will mean in CAP and PPS long term. I found this stock about 6-7 month’s ago while researching new company technologies and ran across a video testimonial from an early patient in the DC area. Sounded very promising, total remission. Sounded very promising. I wish I could find the video. I will search and link it here if I come across it again.
Roger that
Phase 2 timeline estimates, from clinical trails website:
Estimated Study Start Date : August 15, 2018
Estimated Primary Completion Date : August 15, 2020
Estimated Study Completion Date : August 15, 2022
These are currently only estimates. I am sure once the study starts in a few weeks then the progress will reflect in PPS, and begin to draw more interest. I am long minded strategist and believe they will be successful based off of Phase 1 results. I am willing to wait and see 2-4 years from now, and hoping for 5000%+ ROI from my investments so far in this company. Of course there are allot of net sayers as lack of information breads discontent, but once progress information begins to roll out (or even buy out) the train will have already left the station and today’s PPS will be distant memories. Patience will pay off. So far off I’ve been able to lock up a total of about 2 days of average trading days of shares. Hanging in there and putting my money with my mouth. No risk no rewards. Strapped in and ready for takeoff.
Sorry typo not 1/3 but 8% of market Cap value
Today a .5+Mil $ in trades almost 1/3 of the total market cap. I was able to load more today - longs let’s shake the tree and buy more to lock this baby PPS up!! We’ll be seeing many more millionaires at the end of this journey and doing something good to hit cancer hard!
What would you do? Way way back.... On 2/7/11 the OBMP traded a high of $59.72!!
Roll forward to current times, with a successful phase 2 or phase 3 could it get here again??? Go higher? Current market caps aside just ponder the potential and ask yourself is now a good time to buy? No brainer - Definitely!!
Looking to buy more on the dip. I have a significant ask in at .022 just in case. Just working on adding more shares to what I already have. Don’t know if I’ll catch the ask before the bounce. Currently appears to be trading within a .002+\- swing so maybe tomorrow early. Holding long & strong and accumulating ??
Oops my bad correcting post link https://www.otcmarkets.com/stock/OBMP/disclosure
Go to https://www.otcmarkets.com/stock/OBMP/financials you can open both of them there.
Thanks for the info
Great link thanks I think I found OncBioMune trail info, https://clinicaltrials.gov/show/NCT02649439
Take a look
Good question, I see where sponsors of the trails financial disclosures are required by FDA unless they are being reimbursed then not needed. Did not find a regulation requiring financial funds disclosure by the Pharma company for trails.
You are correct, but it is an indication of potential PPS as excitement and trails prove successful more currently in 2016 it was $6.50 so I saying buying at any of today’s PPS is a great deal would you disagree?
Share prices were north of .20 PPS prior to the Mexico company investment now that’s gone likely to see a return to that and more and that was pre phase I completion. Going back even further to 2014, PPS was $51.43! Can you imagine where this could quickly go? Buy now at .04/.05 PPS and.....,WOW